Investors bought shares of CVS Health Corporation (NYSE:CVS) on weakness during trading on Monday. $155.34 million flowed into the stock on the tick-up and $122.84 million flowed out of the stock on the tick-down, for a money net flow of $32.50 million into the stock. Of all stocks tracked, CVS Health Corporation had the 15th highest net in-flow for the day. CVS Health Corporation traded down ($2.51) for the day and closed at $94.04

Several research firms have weighed in on CVS. Citigroup Inc. lifted their price objective on shares of CVS Health Corporation from $105.00 to $115.00 and gave the stock a “neutral” rating in a research report on Monday, May 9th. Vetr raised shares of CVS Health Corporation from a “hold” rating to a “buy” rating and set a $113.29 target price for the company in a research note on Monday, April 4th. Jefferies Group lifted their target price on shares of CVS Health Corporation from $110.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, May 12th. Mizuho reissued a “buy” rating and set a $117.00 target price (up previously from $104.00) on shares of CVS Health Corporation in a research note on Wednesday, May 4th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $115.00 target price (up previously from $110.00) on shares of CVS Health Corporation in a research note on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. CVS Health Corporation currently has an average rating of “Buy” and an average price target of $112.98.

The firm’s 50 day moving average price is $95.72 and its 200-day moving average price is $98.31. The firm has a market cap of $101.00 billion and a price-to-earnings ratio of 20.44.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Tuesday, May 3rd. The pharmacy operator reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.02. During the same quarter in the previous year, the business earned $1.14 earnings per share. The business had revenue of $43.20 billion for the quarter, compared to the consensus estimate of $43.01 billion. The firm’s revenue was up 18.9% on a year-over-year basis. Equities analysts expect that CVS Health Corporation will post $5.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Thursday, July 21st will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.81%. The ex-dividend date is Tuesday, July 19th.

In other CVS Health Corporation news, EVP Troyen A. Brennan sold 7,517 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $105.00, for a total transaction of $789,285.00. Following the transaction, the executive vice president now directly owns 69,601 shares in the company, valued at $7,308,105. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Larry J. Merlo sold 38,247 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $105.00, for a total transaction of $4,015,935.00. Following the transaction, the chief executive officer now owns 280,381 shares in the company, valued at $29,440,005. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of the stock. Toth Financial boosted its position in shares of CVS Health Corporation by 0.8% in the fourth quarter. Toth Financial now owns 94,126 shares of the pharmacy operator’s stock worth $9,203,000 after buying an additional 784 shares during the last quarter. EQIS Capital Management boosted its position in shares of CVS Health Corporation by 248.2% in the fourth quarter. EQIS Capital Management now owns 18,738 shares of the pharmacy operator’s stock valued at $1,832,000 after buying an additional 13,357 shares in the last quarter. Fulton Bank boosted its position in shares of CVS Health Corporation by 44.9% in the fourth quarter. Fulton Bank now owns 16,747 shares of the pharmacy operator’s stock valued at $1,637,000 after buying an additional 5,190 shares in the last quarter. LBA Wealth Management LLC boosted its position in shares of CVS Health Corporation by 3.1% in the fourth quarter. LBA Wealth Management LLC now owns 16,876 shares of the pharmacy operator’s stock valued at $1,650,000 after buying an additional 503 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in shares of CVS Health Corporation by 9.5% in the fourth quarter. Oppenheimer & Co. Inc. now owns 71,424 shares of the pharmacy operator’s stock valued at $6,984,000 after buying an additional 6,215 shares in the last quarter.

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.